Send to:

Choose Destination
See comment in PubMed Commons below
J Paediatr Child Health. 2014 Oct;50(10):E68-71. doi: 10.1111/j.1440-1754.2010.01797.x. Epub 2010 Jul 8.

Lactobacillus reuteri in children with functional abdominal pain (FAP).

Author information

  • 1Pediatric Department, University of Messina, Messina, Children's Hospital G. Di Cristina, Palermo, Pediatric Department, University of Catania, Catania and Pediatric Unit, Vittoria Hospital, Vittoria, Italy.



Functional abdominal pain (FAP) is a frequent condition affecting 10-20% of children and can be considered within the classification of functional gastrointestinal disorders (FGID). The objective of this study was to determine the effect of daily supplementation with the probiotic Lactobacillus reuteri DSM 17938 in children with FAP.


The children (aged 6-16 years) were screened for FAP as defined in the Rome III criteria and 60 patients were recruited in this double-blind, randomised, placebo-controlled trial. The children were randomly allocated to receive either L. reuteri (2×10(8)  CFU/day) or identical placebo for 4 weeks followed by a 4-week follow-up period without supplementation. Frequency and intensity of pain was self-recorded by the subjects.


The L. reuteri-supplemented children had significantly lower pain intensity compared with the placebo controls.


Supplementation with L. reuteri reduced perceived abdominal pain intensity, which may encourage clinicians to use this probiotic in children with FAP.

© 2010 The Authors. Journal compilation © 2010 Paediatrics and Child Health Division (Royal Australasian College of Physicians).


functional abdominal pain; functional gastrointestinal disorders (FGID); probiotics

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk